GPhA Calls for Upholding Established International Nonproprietary Naming (INN) System for Biosimilars at World Health Organization Metting

Published Online: Tuesday, October 22, 2013
Follow Pharmacy_Times:

Geneva, Switzerland (Oct. 22, 2013) — At today’s World Health Organization (WHO) 57th Consultation on International Nonproprietary Names, an open forum for discussion among stakeholders, the Generic Pharmaceutical Association reiterated its call for a consistent, proven international standard for biosimilar naming.

“Biosimilars represent an enormous opportunity to put many of today’s most life-changing medicines in reach for millions more patients,” said Ralph G. Neas President and CEO of GPhA. “It is critical that any decision on naming these products does not jeopardize that potential. That is why we are so pleased that WHO is taking a thoughtful and deliberate approach to reviewing this issue.”

GPhA joined the European Generics Association (EGA) in stressing that the established INN naming system has worked effectively and should be continued. The presentation noted that for more than 50 years, this system has successfully identified drug products and assured practitioners worldwide that the prescribed product has the same active ingredient and clinical effect as the reference product. EGA and GPhA also remarked that their members have successfully and safely produced biosimilars for patients over the past seven years.

GPhA recommended that all biosimilars share the same international nonproprietary name (INN) as the biologic products to which they refer, because by definition they are “highly similar” to the reference biologics and have no clinically meaningful differences that require a unique name. Adding further layers of requirements, GPhA warned, would likely create confusion, slow adoption of biosimilars, and potentially give rise to medical errors. 

This position is shared by GPhA and EGA member company Hospira, which recently released a new policy paper on biosimilars naming, “What’s in a Name? The Importance of Biosimilar Nonproprietary Names for Healthcare Innovation,” by Sumant Ramachandra, MD, PhD. Ramachandra presented on behalf of GPhA at today’s meeting along with David Gaugh, GPhA Senior Vice President, Sciences and Regulatory Affairs.

Biosimilars one pager
Hospira Study
Hospira press release
GPhA Citizen Petition (full)
Summary: GPhA citizen petition on biosimilar naming
Related Articles
The Generic Pharmaceutical Association has serious concerns about the unbalanced structure of the Trans-Pacific Partnership agreement in its current form.
GPhA has agreed to support compromise automatic substitution legislation that would allow interchangeable biologics to be automatically substituted at the pharmacy. This step brings millions of Americans closer to the day when they will be able to access safe alternatives to costly biologic medicines. Indeed, Express Scripts projects savings of $250 billion in 10 years should only the 11 likeliest biosimilars enter the market.
Pharmacists will play key role in bringing biosimilar medications to US markets, both before the therapies receive FDA approval and after they become available.
“GPhA applauds FDA for taking helpful steps to address, and hopefully limit, scenarios in which some brand drug companies misuse Risk Evaluation and Mitigation Strategies programs to thwart competition from more affordable generic drugs. The ongoing abuse of REMS and REMS-like programs costs the American health system and its patients $5.4 billion annually, according to a study conducted by Matrix Global Advisors. Interestingly, as the United States market readies for biosimilars, this same study identifies $140 million in lost savings that would occur for every $1 billion in biologics sales.
Latest Issues